Novartis Investigative Site

Ōsaka-sayama, Osaka 589 8511

0 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia (AML), Carcinoma, Non-Small-Cell Lung, Chronic Myelogenous Leukemia, Hepatocellular Carcinoma (HCC), Myelogenous Leukemia, Chronic, Non-Small Cell Lung Cancer, Solid Malignancies

Studies at this site

• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — Completed
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs — Completed
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression — Completed
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations — Stopped early
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) — Completed
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Completed